Innovenn commences production at new facilities

RNS Number : 5065X

Venn Life Sciences Holdings PLC

20 November 2014

 



Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Innovenn commences production of Labskin at new state of the art facilities

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that its innovation division, Innovenn, has commenced production of its pioneering product Labskin at their new state of the art laboratory facilities in the UK.

Labskin, a human skin equivalent, allows high quality skin research to be carried out in the sponsors own facilities. Unlike most skin models, Labskin provides an environment similar to human skin in that it can house microflora.

The commencement of production at these new facilities marks a milestone for Innovenn as they have sought to streamline operations to deal with larger order volumes and a wider geographic distribution. Innovenn have also recently recruited additional technical staff to assist with production and order fulfillment. 

Tony Richardson, CEO of Venn Life Sciences commented: "We are delighted to be able to offer our clients one of the most exciting skin research products ahead of schedule from our facilities in York. We will continue to work and build capacity in order to increase our worldwide distribution of Labskin and the provision of associated microbiology services."

Enquiries:

Venn Life Sciences Holdings Plc	www.vennlifesciences.com
Tony Richardson, Chief Executive Officer		Tel: [phone]
Declan Service, Managing Director                                       Orla McGuinness, Marketing Manager		Tel: [phone]
Zeus Capital (Nominated Adviser and Broker)
Ross Andrews/Andrew Jones (Corporate Finance)		Tel: [phone]
Dominic Wilson (Institutional Sales)		Tel: [phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

About InnoVenn

InnoVenn (55.6% owned by Venn) is a market development accelerator dedicated to rapidly commercialising proven scientific breakthroughs in the form of products and technologies primarily in Skin Science. These include Labskin the breakthrough research grade human skin testing platform as well as the clinically proven Blemish Control Technology for the professional skincare market. For more information on Innovenn, visit www.innovenn.co.uk

About Venn Life Sciences Limited

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK and Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

 

END

 

 

NRAVKLFFZFFBFBV